摘要
目的探讨胸腺肽α1对慢性阻塞性肺疾病患者急性加重的预防作用及其机制。方法将80例稳定期慢性阻塞性肺疾病患者随机分为治疗组和对照组,对照组给予必要的解痉和祛痰等基础治疗,治疗组在此基础上接受胸腺肽α11.6mg皮下注射,隔日1次,共注射10次;二组患者均观察6个月,每2周经门诊随访1次,进行临床情况评价,并于治疗前、治疗后3个月及6个月检查患者肺功能、血清IgA、IgG、IgM、CD3、CD4和CD8水平。结果在治疗3个月和6个月后,治疗组患者发生急性加重人数和急性加重天数均明显低于对照组(P<0.05),而治疗组患者在治疗后血CD4及CD4/CD8比值明显升高(P<0.05)。结论胸腺肽α1通过增强患者细胞免疫功能,可有效地预防慢性阻塞性肺疾病的急性加重。
Objectives To investigate the prophylactic effect of thymosin α1 and its mechanism on patients with chronic obstructive pulmonary disease.Methods Eighty patients with chronic obstructive pulmonary disease were divided into two groups.In the treatment group,42 patients received thymosin alpha 1 1.6 mg hypodermic injection,quague die alterna,for 10 times.All patients were followed for 6 months,and were assessed the number and days of patients with acute exacerbation at 3 and 6 months.In two groups,before treatment and 3 and 6 months after treatment,the pulmonary function tests were measured,and the blood samples were collected for the measurement of the blood IgA,IgG,IgM,CD3,CD4 and CD8 levels.Results In the treatment group,the number and days of patients with acute exacerbation were significantly lower in comparison with those of the control group.After treatment of thymosin alpha 1,blood CD4 and CD4/CD8 levels were significantly increased.Conclusion Thymosin alpha 1 has a good protection for the acute exacerbation of chronic obstructive pulmonary disease,by incresing body cellular immune activity.
出处
《四川大学学报（医学版）》
CAS
CSCD
北大核心
2008年第4期588-590,共3页
Journal of Sichuan University(Medical Sciences)
关键词
慢性阻塞性肺疾病
急性加重
胸腺肽Α1
T淋巴细胞亚群
Chronic obstructive pulmonary disease Acute exacerbation Thymosin alpha 1 T lymphocyte subset
